Show simple item record

dc.contributor.authorFeigin, Ven_NZ
dc.contributor.authorGBD 2016 Brain and other CNS Cancer Collaboratorsen_NZ
dc.date.accessioned2019-03-18T00:21:24Z
dc.date.available2019-03-18T00:21:24Z
dc.date.copyright2019en_NZ
dc.identifier.citationThe Lancet Neurology. doi: 10.1016/S1474-4422(18)30468-x
dc.identifier.issn1474-4422en_NZ
dc.identifier.urihttp://hdl.handle.net/10292/12362
dc.description.abstractBackground Brain and CNS cancers (collectively referred to as CNS cancers) are a source of mortality and morbidity for which diagnosis and treatment require extensive resource allocation and sophisticated diagnostic and therapeutic technology. Previous epidemiological studies are limited to specific geographical regions or time periods, making them difficult to compare on a global scale. In this analysis, we aimed to provide a comparable and comprehensive estimation of the global burden of brain cancer between 1990 and 2016. Methods We report means and 95% uncertainty intervals (UIs) for incidence, mortality, and disability-adjusted life-years (DALYs) estimates for CNS cancers (according to the International Classification of Diseases tenth revision: malignant neoplasm of meninges, malignant neoplasm of brain, and malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016. Data sources include vital registration and cancer registry data. Mortality was modelled using an ensemble model approach. Incidence was estimated by dividing the final mortality estimates by mortality to incidence ratios. DALYs were estimated by summing years of life lost and years lived with disability. Locations were grouped into quintiles based on the Socio-demographic Index (SDI), a summary indicator of income per capita, years of schooling, and total fertility rate. Findings In 2016, there were 330 000 (95% UI 299 000 to 349 000) incident cases of CNS cancer and 227 000 (205 000 to 241 000) deaths globally, and age-standardised incidence rates of CNS cancer increased globally by 17·3% (95% UI 11·4 to 26·9) between 1990 and 2016 (2016 age-standardised incidence rate 4·63 per 100 000 person-years [4·17 to 4·90]). The highest age-standardised incidence rate was in the highest quintile of SDI (6·91 [5·71 to 7·53]). Age-standardised incidence rates increased with each SDI quintile. East Asia was the region with the most incident cases of CNS cancer for both sexes in 2016 (108 000 [95% UI 98 000 to 122 000]), followed by western Europe (49 000 [37 000 to 54 000]), and south Asia (31 000 [29 000 to 37 000]). The top three countries with the highest number of incident cases were China, the USA, and India. CNS cancer was responsible for 7·7 million (95% UI 6·9 to 8·3) DALYs globally, a non-significant change in age-standardised DALY rate of −10·0% (−16·4 to 2·6) between 1990 and 2016. The age-standardised DALY rate decreased in the high SDI quintile (−10·0% [–27·1 to −0·1]) and high-middle SDI quintile (−10·5% [–18·4 to −1·4]) over time but increased in the low SDI quintile (22·5% [11·2 to 50·5]). Interpretation CNS cancer is responsible for substantial morbidity and mortality worldwide, and incidence increased between 1990 and 2016. Significant geographical and regional variation in the incidence of CNS cancer might be reflective of differences in diagnoses and reporting practices or unknown environmental and genetic risk factors. Future efforts are needed to analyse CNS cancer burden by subtype.
dc.publisherElsevieren_NZ
dc.relation.isreplacedby10292/12512
dc.relation.isreplacedbyhttp://hdl.handle.net/10292/12512
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S147444221830468X?via%3Dihub
dc.rights© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
dc.titleGlobal, Regional, and National Burden of Brain and Other Cns Cancer, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016en_NZ
dc.typeJournal Article
dc.rights.accessrightsOpenAccessen_NZ
dc.identifier.doi10.1016/S1474-4422(18)30468-xen_NZ
aut.relation.endpage393
aut.relation.issue4en_NZ
aut.relation.startpage376
aut.relation.volume18en_NZ
pubs.elements-id352646
aut.relation.journalThe Lancet Neurologyen_NZ


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record